MAPT and Alzheimer disease: In conclusion, alongside how CSF 14-3-3β is routinely used clinically as a biomarker to aid in the diagnosis of sporadic Creutzfeldt–Jakob disease, our study provides additional evidence that CSF 14-3-3β levels are increased in Alzheimer’s disease and that they are associated with other biomarkers of the disease, such as biomarkers of tau pathology and synaptic biomarkers.